Leukocell 2
Introduction

Company name: Pfizer Limited
Address: Ramsgate Road
Sandwich
Kent CT13 9NJ
Telephone: 0845 300 8034 (Out of hours: 01304 616161)
Fax: 01737 332521
Email: UKVetLine@pfizer.com
Website: www.only4vets.co.uk
Presentation
A solution for injection containing inactivated sub-unit antigens (gp 70 and FOCMA) of feline leukaemia virus (FeLV) subtypes A, B and C, minimum 2266 ng/ml of gp 70 antigen. Also contains Alhydrogel 2% 50µl, Quil A 25µg, Thiomersal 0.115mg (maximum), water for injection to 1ml and traces of gentamycin.
Uses
For the active immunisation of healthy cats to reduce persistent viraemia and lymphoid tumours caused by FeLV infection and thereby to reduce other diseases associated with FeLV infection.
Onset of immunity occurs by approximately 3 weeks after the last dose of the Basic Vaccination Scheme.
The duration of immunity is at least 12 months.
Dosage and administration
Shake the vial well immediately before use, and administer the entire contents (1 ml) by subcutaneous injection.
Basic Vaccination Scheme:
In cats aged 9 weeks and more, two doses should be given, with an interval of 3–4 weeks.
If simultaneous immunisation against feline infectious enteritis (panleucopaenia) and respiratory disease due to feline viral rhinotracheitis (FVR) virus and calicivirus is required, Leukocell 2 can be used in place of the diluent to reconstitute Felocell CVR (freeze-dried feline infectious enteritis, viral rhinotracheitis and calicivirus vaccine, living), using the reconstitution method described in the product information for Felocell CVR. Once mixed, the vaccines should be injected immediately via the subcutaneous route.
Re-vaccination:
Annual booster vaccination is recommended.
Contra-indications, warnings, etc
Do not vaccinate unhealthy or pregnant animals.
On very rare occasions, soft painless swellings (<1cm average) may occur after vaccination, which may be evident as painless hard nodules for up to 21 days. Transient increases in rectal temperature for up to 48 hours may also be observed. A small proportion of cats may show reduced activity for 1 or 2 days after vaccination and pain on injection (generally slight) may be observed. Rare occurrences of anaphylaxis and gastro-enteric signs (emesis and diarrhoea) have been reported after vaccination.
When Leukocell 2 and Felocell CVR are administered simultaneously, incidence of local reactions may be increased.
No reactions other than those listed above have been observed after an accidental overdose.
Vaccination is of no known clinical value in cats with pre-existing FeLV infection, nor will it change the natural course of the disease.
If an anaphylactic reaction occurs, institute treatment immediately according to the clinical signs using adrenaline or other appropriate medication.
The use of immunosuppressant drugs or procedures within one month of vaccination is contra-indicated.
The effect of maternally derived antibodies (MDA) on the response to vaccination is not known, but on the basis of published data and field use it is expected that the levels of MDA that will be present at 9 weeks of age will not interfere with the response to vaccination.
Operator warning:
In case of accidental self-injection, wash the area immediately with water. If symptoms develop, seek medical attention showing a copy of the product literature.
Pharmaceutical precautions
Store and transport between 2 and 8°C. Do not freeze.
Do not mix with any other vaccine or immunological product other than Felocell CVR (freeze-dried feline infectious enteritis, viral rhinotracheitis and calicivirus vaccine, living).
No information is available on the safety and efficacy from the concurrent administration of this vaccine with any other except Felocell CVR. It is therefore recommended that no other vaccine than this should be administered within 14 days before or after vaccination with Leukocell 2.
Dispose of waste materials by boiling, incineration or immersion in an appropriate disinfectant in accordance with national requirements.
For animal treatment only.
Keep out of reach of children.
Legal category
POM-V
Packaging Quantities
Packs containing 25 doses of Leukocell 2. Packs of disposable syringes with needles are also available.
Marketing authorisation number
Vm 00057/4114.